AR043612A1 - Derivados de azepan y sus usos - Google Patents

Derivados de azepan y sus usos

Info

Publication number
AR043612A1
AR043612A1 ARP040100854A ARP040100854A AR043612A1 AR 043612 A1 AR043612 A1 AR 043612A1 AR P040100854 A ARP040100854 A AR P040100854A AR P040100854 A ARP040100854 A AR P040100854A AR 043612 A1 AR043612 A1 AR 043612A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
oxygen
atoms
nitrogen
Prior art date
Application number
ARP040100854A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR043612A1 publication Critical patent/AR043612A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP040100854A 2003-03-14 2004-03-15 Derivados de azepan y sus usos AR043612A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45510003P 2003-03-14 2003-03-14
US45941603P 2003-04-01 2003-04-01

Publications (1)

Publication Number Publication Date
AR043612A1 true AR043612A1 (es) 2005-08-03

Family

ID=32994582

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100854A AR043612A1 (es) 2003-03-14 2004-03-15 Derivados de azepan y sus usos

Country Status (6)

Country Link
US (1) US7342007B2 (https=)
EP (1) EP1636196A1 (https=)
JP (1) JP2006520396A (https=)
AR (1) AR043612A1 (https=)
TW (1) TW200504036A (https=)
WO (1) WO2004080983A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
EP1768960A1 (en) * 2004-07-13 2007-04-04 F.Hoffmann-La Roche Ag Sulfonamide derivatives
JP2008523141A (ja) * 2004-12-14 2008-07-03 アストラゼネカ・アクチエボラーグ 新規の分子プローブ
WO2007104933A1 (en) * 2006-03-10 2007-09-20 Astrazeneca Ab Chemical compounds
JP5385904B2 (ja) * 2007-08-14 2014-01-08 イーライ リリー アンド カンパニー γ−セクレターゼ阻害剤
WO2012017410A2 (en) * 2010-08-04 2012-02-09 Azuravax (Proprietary) Limited A stress or strain monitoring system and a method of monitoring stress or strain
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503073A (ja) 1989-01-31 1992-06-04 アボツト・ラボラトリーズ アナフィラトキシン受容体リガンド
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
EP0900791A1 (en) * 1995-12-27 1999-03-10 Ono Pharmaceutical Co., Ltd. Tetrazole derivatives and drugs containing the same as the active ingredient
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
HUP0001232A3 (en) 1996-12-23 2001-02-28 Elan Pharmaceuticals Inc San F Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds
WO1999067221A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO2000002903A1 (en) 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
AU2001243601A1 (en) 2000-03-10 2001-09-24 Ariad Pharmaceuticals, Inc. Caprolactam derivatives and uses thereof
WO2001072324A1 (en) * 2000-03-28 2001-10-04 Bristol-Myers Squibb Pharma Company Lactams as inhibitors of a-beta protein production
US6495540B2 (en) * 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
TW200502221A (en) 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof

Also Published As

Publication number Publication date
JP2006520396A (ja) 2006-09-07
WO2004080983A1 (en) 2004-09-23
US20060183732A1 (en) 2006-08-17
EP1636196A1 (en) 2006-03-22
TW200504036A (en) 2005-02-01
US7342007B2 (en) 2008-03-11

Similar Documents

Publication Publication Date Title
AR039112A1 (es) Inhibidores de quinasas
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR075139A1 (es) Compuestos biciclicos para la reduccion de la produccion de beta-amiloide
AR041440A1 (es) Lactamicos y sus usos
AR046394A1 (es) Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR038326A1 (es) Antibacterianos feniloxazolidinonas sustituidos con heterociclicos biciclicos y composiciones relacionadas y metodos
CO5700770A2 (es) 1,4-diazepinas sustituidas y usos de las mismas
AR084766A1 (es) Compuesto biciclico para modular los receptores acoplados a la proteina g
PE20040832A1 (es) Derivados de indolil pirazinona
AR041734A1 (es) Compuestos de alquino con efecto antagonico de la hcm y medicamentos que contienen estos compuestos
AR107010A1 (es) Derivados de piperidina puenteados
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR063601A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR058296A1 (es) Inhibidores de histona desacetilasa y composicion farmaceutica
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR085099A1 (es) Derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inhibidores de fosfodiesterasas
ECSP088479A (es) Derivados de oxadiazol
CO5650164A2 (es) Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
AR043612A1 (es) Derivados de azepan y sus usos
AR109829A1 (es) Derivados de piperidina puenteados
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR063529A1 (es) Compuestos de pirazolina

Legal Events

Date Code Title Description
FB Suspension of granting procedure